Dyadic to Present at ZAPI Stakeholders Virtual Meeting phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines.
February 1 - 2021 DABANGA SUDAN
The Juba Peace Agreement is signed while the country is drowning - cartoon by Omar Dafallah (RD)
The signing of the Juba Peace Agreement in October was a glimmer of hope for a peaceful future in Sudan, however, there has been little immediate relief to the general public from ongoing economic woes, and chronic shortages of basic commodities such as bread and fuel. This was exacerbated by the second wave of COVID-19 infections.
Protests against the shortages, the March of the Millions expressing dissatisfaction with the slow pace of implementing the aims of the revolution, and frustration and concerns about security issues were widespread. The terms of the Juba agreement were also not welcomed everywhere, and the Eastern Sudan protocol of the agreement triggered clashes.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
February 1, 2021 GMT
Clover LOGO (PRNewsfoto/三叶草生物制药有限公司)
Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial
Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021
CHENGDU, China, Feb. 1, 2021 /PRNewswire/ Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced that the data from its Phase 1 clinical trial evaluating the safety and immunogenicity of its
Is pharma passing the test on access to medicine?
27th January 2021
The
2021 Access to Medicine Index establishes how far the industry has come toward passing that test. It analyses data on 20 of the world’s largest pharmaceutical companies to assess their access-to-medicine performances in relation to 106 low- and middle-income countries and across 82 diseases, conditions and pathogens, including coronaviruses.
It finds that the industry continues to inch forward in integrating access to medicine into governance structures, R&D processes and monitoring efforts, yet their initiatives to address access to specific products – including antibiotics, cancer treatments and heart medicines – remain focused on a few countries. Further, despite years of warnings that novel coronaviruses were among the pathogens most likely to cause a global health emergency, the pharmaceutical industry, as well as society at large, was ill-prepared for the COVID-19 pandemic.